This #WorldLymphomaDay, we’re sharing how we’re working to change the course of care for patients and the larger #lymphoma community.

Today, Genmab colleagues participated in Global Volunteer Day: volunteering 3000+ hours for 50+ local charities in the communities where we live and work. Learn more here: gmab.ly/s93Q50TmnSH. #CommunityAtGenmab

We’re heading to #SOHO2026! Connect with Genmab colleagues at the 14th Annual @SocietyofHemOnc Meeting and visit Booth #176 to learn more about our innovative antibody science and investigational therapies. #Hematology

We are excited to announce that Genmab is now on Facebook and Instagram! These channels offer new ways to share our story and connect with our community. Follow along to explore our science, our people and how we're committed to our goal of improving the lives of people with cancer and other serious diseases. Facebook: facebook.com/profile.php?id=…. Instagram: instagram.com/genmab.biotech

Cervical cancer was one of the most common cancers affecting women in the United Kingdom aged 15-44 in 2023. (3) We’re pushing for change and are committed to improving outcomes. #CervicalCancer #WomensHealth

How can antibody science enable more targeted, personalized approaches in oncology? In this #AntibodyHour 🕙, Marije Overdijk, Head of Early Translational Medicine and Research, shares how her team advances promising antibody medicines from the research bench toward clinical proof of concept. #AntibodyHour #AntibodyScience

#InvestorUpdate: We announced our earnings report for the first half of 2026, highlighting strong execution against our strategic priorities and a strong financial foundation to support long-term growth. Learn more and tune in to our investor call: lnkd.in/eXViMPnE. #Biotech #Earnings #AntibodyMedicines

Happy #NationalInternDay to our incredible Genmab summer interns! This summer, our interns brought fresh perspectives, curiosity, and enthusiasm to teams across Genmab. From R&D and Commercialization to Data, Digital & AI, Corporate Functions, and other teams across the organization, they collaborated, learned, and made meaningful contributions alongside colleagues. Thank you to our interns, managers, mentors, and colleagues for making this a rewarding and successful summer!

At the heart of every scientific advancement is a team united by a shared commitment to innovation and collaboration. In this week's #AntibodyHour 🕙, hear from our colleague Neda Dukanovic Misic, Director, Quality Management & Lab Compliance, Global Lab Management, on how a personal connection to cancer inspires her work supporting the consistency and integrity of our labs—and the science behind potential new medicines.

At Genmab, curiosity and courage drive us to explore bold ideas—always grounded in strong science and teamwork. During this edition of #AntibodyHour 🕙, our colleague Esil shares how she leads oncology programs from discovery toward the clinic with one goal in mind: bringing potential new medicines to patients.

#News: The EU Commission has granted marketing authorization for one of our therapies, developed with @abbvie, as a combination regimen for adults with relapsed/refractory (R/R) follicular #lymphoma (FL). Learn more: gmab.ly/yonP50ZaGuQ

#NewsUpdate: Today, topline results are available from a Phase 3 study in relapsed/refractory diffuse large B-cell #lymphoma (#DLBCL), in partnership with @abbvie. Learn more: gmab.ly/yzJk50ZiuxS

This Cancer Immunotherapy Month, we’re spotlighting our colleague Erik Voets, Associate Director, Product Discovery Lead at Genmab. Erik works on developing innovative immune-based therapies designed to help the body better recognize and target harmful cells At Genmab, we aspire to advance innovative antibody therapies to positively impact patients. Learn more: genmab.com/antibody-science. #CancerImmunotherapyMonth

During this edition of #AntibodyHour 🕙, Farshid Alemdehy, Senior Scientist in Translational Medicine and Research at Genmab, shares how his team works to bridge preclinical and early clinical development to ensure the science behind our medicines translates into meaningful benefits for patients.

We want to hear from you! Answer the poll below to let us know what topic interests you and what you would like to learn more about? Please answer below! ⬇️ What makes you feel most connected to a company’s vision?

We’re headed to #BIO2026 and ready to connect and collaborate with the ambition to transform patients' lives. For more information, please contact licensing@genmab.com #BIOInternationalConvention #Biotech

Leaving #EHA2026 inspired! Grateful to the @EHA_Hematology community for an energizing few days of science, collaboration, and innovation in hematology. A fantastic opportunity to connect, learn, and reframe our focus on helping shape the future of patient care through science and partnership. #Innovation #Hematology

#NewsUpdate: We shared results on one of our assets from two studies developed with @abbvie, in patients with newly diagnosed diffuse large B-cell #lymphoma at #EHA2026 Learn more: gmab.ly/iXO850Z7jy0